These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 23172532)
1. [Predicting value of dynamic alteration of blood neutrophil/lymphocyte ratio on recurrence-free survival in patients with advanced colon cancer after operation and chemotherapy]. Li J; Jia YB; Cai CN; Guan XD; Li PP; Xie YY; Zhang BM Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Nov; 15(11):1171-4. PubMed ID: 23172532 [TBL] [Abstract][Full Text] [Related]
2. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis. Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294 [TBL] [Abstract][Full Text] [Related]
3. [An elevated neutrophil/lymphocyte ratio is associated with poor prognosis in stage II resected colon cancer]. Urrejola GI; Bambs CE; Espinoza MA; Gellona J; Zúñiga AM; Molina ME; Bellolio F; Miguieles R; Campbell JM; Pinedo GA Rev Med Chil; 2013 May; 141(5):602-8. PubMed ID: 24089275 [TBL] [Abstract][Full Text] [Related]
4. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Ding PR; An X; Zhang RX; Fang YJ; Li LR; Chen G; Wu XJ; Lu ZH; Lin JZ; Kong LH; Wan DS; Pan ZZ Int J Colorectal Dis; 2010 Dec; 25(12):1427-33. PubMed ID: 20821217 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy. Noh OK; Oh SY; Kim YB; Suh KW World J Surg; 2017 Nov; 41(11):2898-2905. PubMed ID: 28707088 [TBL] [Abstract][Full Text] [Related]
6. Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. Absenger G; Szkandera J; Stotz M; Postlmayr U; Pichler M; Ress AL; Schaberl-Moser R; Loibner H; Samonigg H; Gerger A Anticancer Res; 2013 Oct; 33(10):4591-4. PubMed ID: 24123035 [TBL] [Abstract][Full Text] [Related]
7. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335 [TBL] [Abstract][Full Text] [Related]
8. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4. el Aziz LM Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855 [TBL] [Abstract][Full Text] [Related]
9. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812 [TBL] [Abstract][Full Text] [Related]
10. Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. Peng W; Li C; Wen TF; Yan LN; Li B; Wang WT; Yang JY; Xu MQ J Surg Res; 2014 Dec; 192(2):402-8. PubMed ID: 24998425 [TBL] [Abstract][Full Text] [Related]
11. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy. Kaneko M; Nozawa H; Sasaki K; Hongo K; Hiyoshi M; Tada N; Murono K; Nirei T; Kawai K; Sunami E; Tsuno NH; Kitayama J Oncology; 2012; 82(5):261-8. PubMed ID: 22538399 [TBL] [Abstract][Full Text] [Related]
12. Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome. Murray NP; Villalon R; Hartmann D; Rodriguez PM; Aedo S Asian Pac J Cancer Prev; 2022 Feb; 23(2):591-599. PubMed ID: 35225472 [TBL] [Abstract][Full Text] [Related]
13. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer. Wang Y; Liu P; Xu Y; Zhang W; Tong L; Guo Z; Ni H Cancer Chemother Pharmacol; 2015 Feb; 75(2):255-62. PubMed ID: 25428515 [TBL] [Abstract][Full Text] [Related]
14. The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction. Yuan D; Zhu K; Li K; Yan R; Jia Y; Dang C J Surg Oncol; 2014 Sep; 110(3):333-40. PubMed ID: 24889121 [TBL] [Abstract][Full Text] [Related]
15. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022 [TBL] [Abstract][Full Text] [Related]
16. Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis. Galizia G; Lieto E; Zamboli A; De Vita F; Castellano P; Romano C; Auricchio A; Cardella F; De Stefano L; Orditura M Surgery; 2015 Jul; 158(1):112-20. PubMed ID: 25818659 [TBL] [Abstract][Full Text] [Related]
17. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435 [TBL] [Abstract][Full Text] [Related]
18. [Assessment value of preoperative neutrophil-lymphocyte ratio for the prognosis of patients with colorectal cancer after radical operation]. Liu HL; Du XH; Sun PM; Xiao CH; Zou ZY; Xu YX Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Aug; 16(8):723-6. PubMed ID: 23980040 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy. Cha YJ; Park EJ; Baik SH; Lee KY; Kang J Sci Rep; 2019 Aug; 9(1):11617. PubMed ID: 31406179 [TBL] [Abstract][Full Text] [Related]
20. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea. Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]